# Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

> **NCT04120246** · PHASE1 · SUSPENDED · sponsor: **Veana Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- HER2 Positive Breast Carcinoma
- Metastatic Breast Carcinoma
- Refractory Breast Carcinoma

## Interventions

- **DRUG:** Alpha-tocopheryloxyacetic Acid
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT04120246
- **Lead sponsor:** Veana Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-04-08
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-02-01
- **Target enrollment:** 24 (ESTIMATED)
- **Why stopped:** Study placed on hold.
- **Last updated:** 2024-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120246, "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04120246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*